Growth Metrics

Biogen (BIIB) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$48.9 million.

  • Biogen's Income from Continuing Operations fell 11833.52% to -$48.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2078.79%. This contributed to the annual value of $1.3 billion for FY2025, which is 2078.79% down from last year.
  • Latest data reveals that Biogen reported Income from Continuing Operations of -$48.9 million as of Q4 2025, which was down 11833.52% from $466.5 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Income from Continuing Operations ranged from a high of $1.1 billion in Q3 2022 and a low of -$68.3 million during Q3 2023
  • Its 5-year average for Income from Continuing Operations is $436.9 million, with a median of $391.0 million in 2024.
  • In the last 5 years, Biogen's Income from Continuing Operations soared by 153848.17% in 2022 and then tumbled by 11833.52% in 2025.
  • Over the past 5 years, Biogen's Income from Continuing Operations (Quarter) stood at -$38.2 million in 2021, then skyrocketed by 1538.48% to $549.5 million in 2022, then crashed by 54.7% to $248.9 million in 2023, then grew by 7.15% to $266.7 million in 2024, then tumbled by 118.34% to -$48.9 million in 2025.
  • Its Income from Continuing Operations was -$48.9 million in Q4 2025, compared to $466.5 million in Q3 2025 and $634.8 million in Q2 2025.